Journal Article

Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing

Bacares, Ruben, Rana, Satshil, Ptashkin, Ryan N., Salles, Gilles, van den Brink, Marcel R. M., Park, Jae H., Kiecka, Iwona, Giralt, Sergio, Borsu, Laetitia, Roshal, Mikhail, Yabe, Mariko, Son-Garcia, Julie, Zhu, Menglei, Xiao, Wenbin, Benhamida, Jamal, Suehnholz, Sarah P., Nafa, Khedoudja, Younes, Anas, Wang, Jiajing, Casanova, Jacklyn, Levine, Ross L., Mohanty, Abhinita S., Liu, Ying, Stein, Eytan M., Batlevi, Connie Lee, Ewalt, Mark D., de Bruijn, Ino, Rampal, Raajit, Tallman, Martin, Haque, Mohammad S., Berger, Michael F., Seshan, Venkatraman E., Lin, Yun-Te David, Lachhander, Sean, Jayakumaran, Gowtham, Wang, Wei, Perales, Miguel-Angel, Razumova, Anna, Aypar, Umut, Arcila, Maria E., Bowman, Anita S., Balakrishnan Rema, Anoop, Zhang, Yanming, Zehir, Ahmet, Mato, Anthony R., Vanderbilt, Chad, Dogan, Ahmet, Abdel-Wahab, Omar, Brannon, A. Rose, Ladanyi, Marc, Benayed, Ryma, Petrova-Drus, Kseniya, Chakravarty, Debyani, Yao, JinJuan, Rijo, Ivelise

2023

Overview

Genomic profiling of hematologic malignancies has augmented our understanding of variants that contribute to disease pathogenesis and supported development of prognostic models that inform disease management in the clinic. Tumor only sequencing assays are limited in their ability to identify definitive somatic variants, which can lead to ambiguity in clinical reporting and patient management. Here, we describe the MSK-IMPACT Heme cohort, a comprehensive data set of somatic alterations from paired tumor and normal DNA using a hybridization capture-based next generation sequencing platform. We highlight patterns of mutations, copy number alterations, and mutation signatures in a broad set of myeloid and lymphoid neoplasms. We also demonstrate the power of appropriate matching to make definitive somatic calls, including in patients who have undergone allogeneic stem cell transplant. We expect that this resource will further spur research into the pathobiology and clinical utility of clinical sequencing for patients with hematologic neoplasms. Targeted sequencing panels such as MSK-IMPACT have been successfully used to profile solid tumours in clinical settings. Here, the authors develop and implement the MSK-IMPACT Heme sequencing panel and platform to profile haematologic malignancies using paired tumor and normal tissues.

• Publisher: Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
• Subject: 45/23 / 692/4017 / 692/4028/67/1990 / Allografts / Blood cancer / Copy number / DNA / Hematologic Neoplasms - diagnosis / Hematologic Neoplasms - genetics / Hematologic Neoplasms - therapy / Heme / High-Throughput Nucleotide Sequencing / Humanities and Social Sciences / Humans / Hybridization / Malignancy / multidisciplinary / Mutation / Neoplasms / Neoplasms - genetics / Next-generation sequencing / Pathogenesis / Science / Science (multidisciplinary) / Solid tumors / Stem cell transplantation / Stem cells / Tumors